Pyrrolo [2,1-c] [1,4] benzodiazepine (PBD) is a class of natural products obtained from various actinomycetes which have both anti-tumor and antibiotic activities and can bind to specific sequences of DNA. PBD-dilactam was initially produced using isatoic anhydride and (L)-proline which was then converted to the PBD-thiolactam using Lawesson's reagent. Reaction of thiolactam with hydrazine in ethanol afforded PBD-11-hydrazinyl. Condensation of 11-hydrazinyl PBD with aldehydes possessing various substitutions was performed to obtain (S,E)-11-[2-(arylmethylene) hydrazono] pyrrolo [2,1-c] [1,4] benzodiazepine derivatives. 1HNMR, 13C-NMR, DEPT, IR, GC-MS and X-ray crystallography were used for the characterization. Inhibition activity of the products were carried out using TEM-1, AmpC and P99 β-lactamases. A minimal inhibition growth of 25% was observed for one of the selected PBDs on cancer cell line. A promising result was observed on preliminary cannabinoid binding activity test on one of the compounds.

Submitted by Renata Lopes (renatasil82@gmail.com) on 2016-09-27T14:21:32Z No. of bitstreams: 1 osmarnascimentosilva.pdf: 5346948 bytes, checksum: c6c4bb9eae4172e04c4553f57d4e27d0 (MD5) / Approved for entry into archive by Diamantino Mayra (mayra.diamantino@ufjf.edu.br) on 2016-09-27T15:15:36Z (GMT) No. of bitstreams: 1 osmarnascimentosilva.pdf: 5346948 bytes, checksum: c6c4bb9eae4172e04c4553f57d4e27d0 (MD5) / Made available in DSpace on 2016-09-27T15:15:36Z (GMT). No. of bitstreams: 1 osmarnascimentosilva.pdf: 5346948 bytes, checksum: c6c4bb9eae4172e04c4553f57d4e27d0 (MD5) Previous issue date: 2015-04-28 / CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Com o aumento na incidência de infecções resistentes a múltiplos antibióticos, existe hoje um grande interesse pelos peptídeos antimicrobianos (PAMs) como modelos para a produção de novos antibióticos. Os PAMs são mediadores multifuncionais da resposta imune inata, com atividade antibacteriana direta. O uso de PAMs como agentes terapêuticos tem algumas limitações, como a estabilidade, a toxicidade e alta massa molecular. Apesar dessas limitações, eles apresentam propriedades compensatórias, como imunomodulatória e antitumoral bem como a capacidade de inibir β-lactamases. O desenho racional de PAMs tem sido usado para gerar análogos com atividade melhorada. No presente trabalho avaliamos a atividade antibacteriana in vitro e in vivo da clavanina A e através da modificação incremental criamos dois análogos dos peptídeos mostoparano-L e clavanina A (clavanina-MO e mastoparanoMO),além disso, utilizamos o desenho racional de peptídeos para a criação de dois inibidores de β-lactamase (dBLIPs 1 e 2). A clavanina A mostrou se eficiente na eliminação de S. aureus em um modelo de infecção de ferida e impediu o início da sepse e, assim, reduziu a mortalidade de camundongos infectados em um modelo de infecção bacteriana sistêmica. A clavanina-MO e mastoparano-MO impediram o crescimento de bactérias planctônicas e levaram à erradicação de biofilmes bacterianos maduros. Os peptídeos modificados mostram-se promissores como agentes terapêuticos contra infecções bacterianas sistêmicas e biofilmes causadas por uma variedade de bactérias. dBLIP-1 e dBLIP-2 em combinação com antibióticos convencionais foram eficazes na eliminação de Escherichia coli e Staphylococcus aureus que expressam β-lactamases em um modelo murino de infecção sistêmica. dBLIPs 1 e 2 fornecem pistas para superar a resistência à base de β-lactamase. / With the increased incidence of multiple antibiotic resistant infections, there is huge interesting in antimicrobial peptides (AMPs) as templates to produce novel antibiotics. The AMPs are multifunctional mediators of innate immune response with direct antibacterial activities. Nevertheless, the use of AMPs as therapeutic agents has certain limitations such as stability, toxicity and high molecular mass. Despite such limitations, they show additional properties such as antitumor and immunomodulatory as well as the ability to inhibit β-lactamases. Furthermore, the rational AMPs design has been used to produce analogues with improved activity. In the present study, we utilized the rational AMPs design for generation of two β-lactamase inhibitors (dBLIPs 1 and 2) and through two incremental modification created analogues of clavanin A and mostoparan-L (clavanin-MO and mastoparan-MO respectively) peptides. Both inhibitors in combination with conventional antibiotics were effective for control of Staphylococcus aureus and Escherichia coli expressing β-lactamase in a murine model of systemic infection. dBLIPs 1 and 2 provide clues to overcome resistance to β-lactamase base. The clavanin-MO and mastoparan-MO prevented the growth of planktonic bacteria, leading to the mature biofilm eradication of pathogenic Gram-negative and -positive. The clavanina-MO and mastoparan-MO are promising therapeutic agents against systemic infections and bacterial biofilms caused by a wide bacterial variety.